Harvard Bioscience Croissance future
Future contrôle des critères 0/6
Harvard Bioscience devrait augmenter ses bénéfices et ses revenus de 78.6% et de 5% par an respectivement, tandis que le BPA devrait croître de croître de 80.6% par an.
Informations clés
78.6%
Taux de croissance des bénéfices
80.65%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 18.6% |
| Taux de croissance des recettes | 5.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 12 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Aug 13
HBIO: Profitability And Cash Flow Improvements Will Support Higher Future Multiple
Analysts have raised the Harvard Bioscience price target to $7.50 from $6. This reflects their view that recent profitability and cash flow efforts could support a higher future P/E multiple.Mise à jour du récit • Jun 12
HBIO: Reverse Split And 2026 Execution Risks Will Pressure Overvalued Shares
Analysts have lifted their price target on Harvard Bioscience to $6.00, primarily reflecting the updated modeling of the recent 1-for-10 reverse stock split. What's in the News Harvard Bioscience issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.5 million to US$22.5 million.Mise à jour du récit • May 29
HBIO: Reverse Split And 2026 Execution Uncertainty Will Shape Balanced Outlook
Analysts have updated their models for Harvard Bioscience following the 1:10 reverse split, lifting the stated price target from $0.60 to $6 as they align their valuation work with the new share count and revised long term assumptions on growth, margins and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are treating the 1:10 reverse split as a housekeeping move that aligns the share price, share count and stated price target.Article d’analyse • May 07
When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...Mise à jour du récit • Apr 30
HBIO: Reverse Split And 2026 Outlook Will Frame Balanced Risk Reward
Narrative Update: Harvard Bioscience Analysts have reset Harvard Bioscience's price target to $6.00 from $0.60, aligning with the recent 1:10 reverse split and updated revenue expectations for 2026. Analyst Commentary Recent commentary around Harvard Bioscience focuses on how the reverse split and updated 2026 revenue expectations feed into valuation and execution risk.Mise à jour du récit • Apr 12
HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside Potential
Narrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.Mise à jour du récit • Mar 29
HBIO: Reverse Split And Cost Savings Program Will Support Future Recovery Potential
Analysts have reset their price target for Harvard Bioscience from $0.60 to $6.00, reflecting the recent 1 for 10 reverse split and updated modeling rather than a change in the underlying view on the business. Analyst Commentary Recent research updates on Harvard Bioscience have focused on recalibrating models and targets to reflect the 1 for 10 reverse split and revised revenue expectations, rather than a wholesale change in long term conviction.Mise à jour du récit • Mar 15
HBIO: Reset Expectations And Manufacturing Shift Will Set Up Recovery Potential
Analysts have cut their price target on Harvard Bioscience from $2.00 to $0.60, citing a reduced 2026 revenue estimate of $89.2m versus $95.6m previously and stating that the timing of any recovery is still hard to pinpoint. Analyst Commentary Recent commentary around Harvard Bioscience is focused squarely on the reset to expectations and what it could imply for the share price and business execution over the next few years.Article d’analyse • Dec 04
Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce
Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 27% gain in the last month...Article d’analyse • Oct 20
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough
Harvard Bioscience, Inc.'s ( NASDAQ:HBIO ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy...Mise à jour du récit • Sep 11
Demographic Shifts And NIH Funding Will Unlock Biomedical Potential
Analysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook. Analyst Commentary Uncertainty surrounding basic research funding potentially impacting sector performance.Article d’analyse • Aug 14
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target
NasdaqGM:HBIO 1 Year Share Price vs Fair Value Explore Harvard Bioscience's Fair Values from the Community and select...Article d’analyse • Jul 23
Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 29
Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 26% in...Nouveau récit • May 15
Expanding SoHo, BTX, And Mesh MEA Will Open New Markets
Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.Article d’analyse • May 02
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), might not be a large cap stock, but it saw significant share price movement...Article d’analyse • Apr 11
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 49% in...Article d’analyse • Feb 07
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Article d’analyse • Feb 07
Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Article d’analyse • Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it saw a significant share price...Article d’analyse • Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is...Article d’analyse • Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has done very well over the last month, posting an excellent...Article d’analyse • Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.55 Current...Article d’analyse • Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has fared very poorly over the last month, falling by a...Article d’analyse • Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.84 Harvard...Article d’analyse • Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 95 | -2 | 2 | 5 | 2 |
| 12/31/2026 | 90 | -9 | -1 | 3 | 2 |
| 6/30/2026 | 88 | -10 | -2 | 1 | N/A |
| 3/31/2026 | 86 | -10 | 1 | 3 | N/A |
| 12/31/2025 | 87 | -57 | 5 | 7 | N/A |
| 9/30/2025 | 87 | -54 | 7 | 9 | N/A |
| 6/30/2025 | 89 | -57 | 4 | 7 | N/A |
| 3/31/2025 | 91 | -58 | 0 | 3 | N/A |
| 12/31/2024 | 94 | -12 | -2 | 1 | N/A |
| 9/30/2024 | 98 | -14 | 0 | 4 | N/A |
| 6/30/2024 | 101 | -11 | 6 | 9 | N/A |
| 3/31/2024 | 107 | -9 | 11 | 14 | N/A |
| 12/31/2023 | 112 | -3 | 12 | 14 | N/A |
| 9/30/2023 | 113 | -3 | 11 | 12 | N/A |
| 6/30/2023 | 114 | -5 | 7 | 9 | N/A |
| 3/31/2023 | 115 | -2 | 4 | 5 | N/A |
| 12/31/2022 | 113 | -10 | 0 | 1 | N/A |
| 9/30/2022 | 118 | -7 | -3 | -1 | N/A |
| 6/30/2022 | 121 | -4 | -4 | -3 | N/A |
| 3/31/2022 | 121 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 119 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 117 | -2 | 2 | 4 | N/A |
| 6/30/2021 | 111 | -3 | 5 | 6 | N/A |
| 3/31/2021 | 105 | -4 | 6 | 7 | N/A |
| 12/31/2020 | 102 | -8 | 8 | 9 | N/A |
| 9/30/2020 | 102 | -7 | 8 | 9 | N/A |
| 6/30/2020 | 105 | -8 | 9 | 11 | N/A |
| 3/31/2020 | 112 | -7 | N/A | 9 | N/A |
| 12/31/2019 | 116 | -5 | N/A | 8 | N/A |
| 9/30/2019 | 119 | -2 | N/A | 8 | N/A |
| 6/30/2019 | 120 | 0 | N/A | 4 | N/A |
| 3/31/2019 | 122 | -1 | N/A | 4 | N/A |
| 12/31/2018 | 121 | -4 | N/A | 3 | N/A |
| 9/30/2018 | 109 | -8 | N/A | -1 | N/A |
| 6/30/2018 | 99 | -8 | N/A | 3 | N/A |
| 3/31/2018 | 86 | -7 | N/A | 2 | N/A |
| 12/31/2017 | 77 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 82 | -3 | N/A | 4 | N/A |
| 6/30/2017 | 88 | -4 | N/A | 5 | N/A |
| 3/31/2017 | 96 | -4 | N/A | 5 | N/A |
| 12/31/2016 | 105 | -4 | N/A | 5 | N/A |
| 9/30/2016 | 106 | -20 | N/A | 5 | N/A |
| 6/30/2016 | 107 | -19 | N/A | 2 | N/A |
| 3/31/2016 | 110 | -18 | N/A | 0 | N/A |
| 12/31/2015 | 109 | -19 | N/A | 1 | N/A |
| 9/30/2015 | 111 | -2 | N/A | 0 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: HBIO devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: HBIO devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: HBIO devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de HBIO ( 5% par an) devrait croître plus lentement que le marché de US ( 13.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de HBIO ( 5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de HBIO devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/13 12:21 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Harvard Bioscience, Inc. est couverte par 6 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Timothy Chiang | Northland Capital Markets |